Trial Profile

NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms NEOPRISM-CRC

Most Recent Events

17 Apr 2026 Planned number of patients changed from 78 to 88.
17 Apr 2026 Planned End Date changed from 1 Dec 2028 to 31 Jul 2029.
17 Apr 2026 Planned primary completion date changed from 1 Feb 2026 to 31 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com